{"id":15772,"date":"2023-09-22T21:11:43","date_gmt":"2023-09-22T21:11:43","guid":{"rendered":"https:\/\/prosfunds.com\/investing\/kezar-life-sciences-shares-rise-after-deal-with-everest-medicines\/"},"modified":"2023-09-22T21:11:44","modified_gmt":"2023-09-22T21:11:44","slug":"kezar-life-sciences-shares-rise-after-deal-with-everest-medicines","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=15772","title":{"rendered":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines"},"content":{"rendered":"
\n

By Stephen Nakrosis<\/p>\n

<\/pre>\n
Kezar Life Sciences shares were trading higher in Wednesday’s after-hours market, following the entry of an agreement with biotechnology company Everest Medicines to develop and commercialize Zetomipzomib for lupus nephritis and other potential indications in Asia.<\/p>\n
\n
Under the terms of the deal, Kezar is eligible to receive up to $132.5 million in total payments, along with tiered royalties. Everest Medicines will also pay tiered royalties on net sales, the companies said.<\/p>\n
Everest Medicines will gain exclusive rights to develop and commercialize Zetomipzomib in several Asian countries.<\/p>\n
At 6:43 p.m. ET, Kezar shares had risen 12%, to $1.28 a share. The stock, which touched a 52-week low of $1.12 earlier Wednesday, closed the day’s trading with a 4.2% loss, at $1.14.<\/p>\n
<\/pre>\n
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com<\/p>\n
<\/pre>\n<\/p><\/div>\n<\/div>\n
Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday’s after-hours market, following the entry of an agreement with biotechnology company Everest Medicines to develop and commercialize Zetomipzomib for lupus nephritis and other potential indications in Asia. Under the terms of the deal, Kezar is eligible to receive up to $132.5 million in […]<\/p>\n","protected":false},"author":1,"featured_media":3704,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[32],"tags":[],"class_list":{"0":"post-15772","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"yoast_head":"\nKezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds<\/title>\n<meta name=\"description\" content=\"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=15772\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=15772\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-22T21:11:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-22T21:11:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=15772#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=15772\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"Kezar Life Sciences Shares Rise After Deal With Everest Medicines\",\"datePublished\":\"2023-09-22T21:11:43+00:00\",\"dateModified\":\"2023-09-22T21:11:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=15772\"},\"wordCount\":143,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=15772#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=15772\",\"url\":\"https:\/\/prosfunds.com\/?p=15772\",\"name\":\"Kezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2023-09-22T21:11:43+00:00\",\"dateModified\":\"2023-09-22T21:11:44+00:00\",\"description\":\"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=15772#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=15772\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=15772#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences Shares Rise After Deal With Everest Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds","description":"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=15772","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds","og_description":"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with","og_url":"https:\/\/prosfunds.com\/?p=15772","og_site_name":"Prosfunds","article_published_time":"2023-09-22T21:11:43+00:00","article_modified_time":"2023-09-22T21:11:44+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=15772#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=15772"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines","datePublished":"2023-09-22T21:11:43+00:00","dateModified":"2023-09-22T21:11:44+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=15772"},"wordCount":143,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=15772#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=15772","url":"https:\/\/prosfunds.com\/?p=15772","name":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2023-09-22T21:11:43+00:00","dateModified":"2023-09-22T21:11:44+00:00","description":"By Stephen Nakrosis Kezar Life Sciences shares were trading higher in Wednesday's after-hours market, following the entry of an agreement with","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=15772#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=15772"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=15772#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences Shares Rise After Deal With Everest Medicines"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/15772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15772"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/15772\/revisions"}],"predecessor-version":[{"id":15773,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/15772\/revisions\/15773"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/3704"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}